Trials / Completed
CompletedNCT02579915
Developing a Low-Intensity Primary Care Intervention for Anxiety Disorders (AIM-PC)
Phase 2 Randomized Controlled Trial of Attention and Interpretation Modification (AIM) for Anxiety Disorders in Primary Care
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Brown University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to develop a personalized, user-friendly computerized treatment for anxiety disorders linked to primary care. The computerized treatment is a type of Cognitive Bias Modification, which targets attention and interpretation biases known to maintain anxiety disorders.
Detailed description
The primary goals of our 3-year, 2-phase project are to develop AIM for primary care linkage and assess its feasibility and acceptability. This protocol description only pertains to Phase 2 (Randomized Controlled Trial). 42 primary care patients with primary Generalized Anxiety Disorder, Social Anxiety Disorder, and/or Panic Disorder (with or without Agoraphobia) will be randomly assigned to the AIM treatment or to a symptom tracking control group. Full assessments will occur pre- and post-treatment and 3-months follow-up. A mid-treatment assessment will include measures of cognitive biases and the primary outcome. Weekly measures of anxiety and depression will be collected, as will feedback from patients and PCPs about the research and delivery procedures.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | FaceAnxiety | Computerized treatment targeting mental habits and primary care linkage. |
| BEHAVIORAL | Symptom Tracking | Weekly self-assessment with validated questionnaires and primary care linkage |
Timeline
- Start date
- 2015-09-01
- Primary completion
- 2018-12-31
- Completion
- 2018-12-31
- First posted
- 2015-10-20
- Last updated
- 2020-02-07
- Results posted
- 2020-02-07
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02579915. Inclusion in this directory is not an endorsement.